All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired
- PMID: 8617810
- DOI: 10.1074/jbc.271.9.5251
All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired
Abstract
Four transmembrane tyrosine kinases constitute the ErbB receptor family: the epidermal growth factor (EGF) receptor, ErbB-2, ErbB-3, and ErbB-4. We have measured the endocytic capacities of all four members of the EGF receptor family, including ErbB-3 and ErbB-4, which have not been described previously. EGF-responsive chimeric receptors containing the EGF receptor extracellular domain and different ErbB cytoplasmic domains (EGFR/ErbB) have been employed. The capacity of these growth factor-receptor complexes to mediate 125I-EGF internalization, receptor down-regulation, receptor degradation, and receptor co-immunoprecipitation with AP-2 was assayed. In contrast to the EGF receptor, all EGFR/ErbB receptors show impaired ligand-induced rapid internalization, down-regulation, degradation, and AP-2 association. Also, we have analyzed the heregulin-responsive wild-type ErbB-4 receptor, which does not mediate the rapid internalization of 125I-heregulin, demonstrates no heregulin-regulated receptor degradation, and fails to form association complexes with AP-2. Despite the substantial differences in ligand-induced receptor trafficking between the EGF and ErbB-4 receptors, EGF and heregulin have equivalent capacities to stimulate DNA synthesis in quiescent cells. These results show that the ligand-dependent down-regulation mechanism of the EGF receptor, surprisingly, is not a property of any other known ErbB receptor family member. Since endocytosis is thought to be an attenuation mechanism for growth factor-receptor complexes, these data imply that substantial differences in attenuation mechanisms exist within one family of structurally related receptors.
Similar articles
-
Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities.J Biol Chem. 1996 Mar 15;271(11):6071-6. doi: 10.1074/jbc.271.11.6071. J Biol Chem. 1996. PMID: 8626392
-
Epidermal growth factor (EGF) modulation of feline sarcoma virus fms tyrosine kinase activity, internalization, degradation, and transforming potential in an EGF receptor/v-fms chimera.J Virol. 1994 Jan;68(1):411-24. doi: 10.1128/JVI.68.1.411-424.1994. J Virol. 1994. PMID: 8254751 Free PMC article.
-
Heregulin degradation in the absence of rapid receptor-mediated internalization.Exp Cell Res. 1997 Apr 10;232(1):167-72. doi: 10.1006/excr.1997.3515. Exp Cell Res. 1997. PMID: 9141633
-
Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research.Breast Cancer Res Treat. 1995 Jul;35(1):115-32. doi: 10.1007/BF00694752. Breast Cancer Res Treat. 1995. PMID: 7612898 Review.
-
The type 1 (EGFR-related) family of growth factor receptors and their ligands.Prog Growth Factor Res. 1992;4(1):1-24. doi: 10.1016/0955-2235(92)90002-y. Prog Growth Factor Res. 1992. PMID: 1355372 Review.
Cited by
-
An integrated model of epidermal growth factor receptor trafficking and signal transduction.Biophys J. 2003 Aug;85(2):730-43. doi: 10.1016/s0006-3495(03)74516-0. Biophys J. 2003. PMID: 12885624 Free PMC article.
-
Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells.FASEB J. 2009 Jun;23(6):1935-45. doi: 10.1096/fj.08-121947. Epub 2009 Feb 4. FASEB J. 2009. PMID: 19193720 Free PMC article.
-
Nuclisome: a novel concept for radionuclide therapy using targeting liposomes.Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):114-23. doi: 10.1007/s00259-009-1225-7. Eur J Nucl Med Mol Imaging. 2010. PMID: 19662408
-
The Mysterious Ways of ErbB2/HER2 Trafficking.Membranes (Basel). 2014 Aug 6;4(3):424-46. doi: 10.3390/membranes4030424. Membranes (Basel). 2014. PMID: 25102001 Free PMC article. Review.
-
Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):527-40. doi: 10.1007/s10928-015-9444-y. Epub 2015 Sep 12. J Pharmacokinet Pharmacodyn. 2015. PMID: 26364301
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous